癌细胞中的失调YY1-EZH2-RKIP轴和免疫逃避
Talia Festekdjian1, Benjamin Bonavida1
1Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, CA 90095, USA.
通过向YY1-EZH2-RKIP轴,可以克服癌症免疫疗法抵抗性. 这一轴调节免疫逃避,其抑制可能恢复不响应的患者的抗瘤反应.
科学领域:
- 癌症学
- 免疫学
- 分子生物学
背景情况:
- 免疫疗法在癌症治疗中表现有前途,但由于免疫规避, 一部分患者仍然没有反应.
- 识别免疫规避的分子机制对于开发新型向治疗来提高免疫疗法的有效性至关重要.
研究的目的:
- 描述阴阳1 (YY1),EZH2和RKIP (PEBP1) 在癌症免疫逃避中的作用.
- 阐明涉及YY1,EZH2和RKIP失调的分子调节作用和信号通路.
- 确定YY1-EZH2-RKIP轴作为克服免疫疗法耐药性的潜在治疗目标.
主要方法:
- 对分子调节作用和信号通路的分析.
- 基因产品失调的特征 (过度表达/过低表达).
- 在YY1,EZH2和RKIP之间识别交叉通话信号通道.
主要成果:
- 确定了YY1,EZH2和RKIP作为免疫规避的关键基因产物.
- 描述了导致YY1和EZH2过度表达和RKIP过度表达的分子通路.
- 确定了失调的YY1-EZH2-RKIP轴及其在调节免疫逃避中的作用.
结论:
- YY1-EZH2-RKIP轴是抑制癌症免疫逃逸的新疗法目标.
- 通过抑制YY1或EZH2或诱导RKIP来准这一轴,可以恢复抗瘤免疫疗法.
- 需要对针对这一轴的药物进行进一步的临床前研究,重点是瘤特异性输送.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
09:55All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
相关概念视频
Induced Pluripotent Stem Cells
Somatic...
Abnormal Proliferation
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Epigenetic Regulation
X-chromosome...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mechanisms of Retrovirus-induced Cancers
